The Arbor management team is composed of seasoned industry professionals who collectively have decades of experience and expertise in the pharmaceutical industry spanning a wide array of disciplines. Through its comprehensive network of industry partners and corporate leadership, Arbor is poised to rapidly introduce novel treatments that will enhance the treatment and management of diseases in carefully selected specialty areas.
Brian Adams, PhD, MBA
Vice President, Business Development
Dr. Adams has a career of over 15 years in the life sciences in both academia and industry. Prior to joining Arbor, he served as Head of Business Development at Cornerstone Therapeutics and Senior Director of Business Development at Shionogi Pharma (formerly Sciele Pharma). Brian originally started with Shionogi as the Intellectual Property Manager and was responsible for handling the company’s patents and trademarks. Before working for Shionogi, he served as a patent agent and scientific advisor at Pabst Patent Group LLP and Holland & Knight, LLP in the areas of biotechnology and chemistry. He has been very active in the Southeast life sciences community and is a member of the SE BIO Board of Directors. Brian has earned a B.S. in Biology from Wake Forest University, a PhD in Molecular and Systems Pharmacology from Emory University, and an MBA from the University of Georgia.
Vice President, General Counsel and Chief Compliance Officer
Jeff has over 10 years of experience as a General Counsel and Chief Compliance Officer in life sciences companies and over 20 years of legal experience. Jeff was previously the Vice President, General Counsel and Chief Compliance Officer for Alimera Sciences, a publicly trade pharmaceutical company and before that held the same position with CryoLife, a publicly traded biotechnology company. Prior to that Jeff was in-house at Waste Management focused on mergers and acquisitions and was an associate in the Corporate department of Arnall Golden Gregory LLP, an Atlanta based law firm. He holds a J.D. from the University of Chicago Law School and a B.A. in History and Economics from the University of Tennessee.
Steven Caras, MD, PhD
Vice President, Clinical Development
Dr. Steven Caras is a gastroenterologist and biomedical engineer. He has a Bachelors degree in Chemical Engineering from Arizona State University and Masters and Ph.D. degrees in Bioengineering from the University of Utah in Salt Lake City. Steve obtained his medical degree from the University of Miami. He did his residency training in internal medicine at Washington University in St. Louis and his gastroenterology fellowship at University of Virginia in Charlottesville. After his gastroenterology fellowship, Steve worked as a medical reviewer in the Cardio-Renal Division of FDA, where he was mainly involved in antihypertensive and antiarrhythmic drugs. Dr. Caras has over 16 years of experience in all aspects of Phase I-Phase IV clinical development and medical affairs and has worked for Solvay Pharmaceuticals and for PAREXEL, a large CRO. Steve currently volunteers for a local chamber of commerce which evaluates pharmaceutical and medical device companies and provides these companies with essential development, regulatory, and business feedback. He also serves on the Kennesaw State University Advisory Board for the College of Science and Mathematics.
Mary Lou Freathy, JD
Vice President, Regulatory Affairs, Quality, & Manufacturing
Mary Lou has more than 30 years of pharmaceutical experience in quality, regulatory affairs, and compliance including over 15 years supporting the growth and compliance of life science companies. Mary Lou was previously Senior Vice President of Quality, Regulatory Affairs, and Chief Compliance Officer of G&W Laboratories. Prior to that, she held several executive managerial positions at Paddock Laboratories, Pliva, Inc., and Dey Laboratories where she started her pharmaceutical career. Mary Lou belongs to several professional societies including RAPS, PDA, ISPE, and ASQ. She holds a J.D. from the Empire School of Law, and a B.A. in Chemistry from the State University of New York. She is also a Certified Compliance Professional.
Vice President, Commercial Operations
Kevin Guthrie brings 33 years of experience in the Healthcare Industry, most recently serving as President of HealthLink Dimensions. During his time with HealthLink Dimensions, Kevin has guided the company to record client and revenue growth, resulting in recognition as one of America’s fastest-growing private companies for five consecutive years. Previously he served in roles as Vice President of Marketing, Sales, and Operations for Solvay Pharmaceuticals, with US sales of $1.5B. He has also held Sales, Marketing, and Operational leadership roles within Bristol-Myers Squibb. During his time with Solvay and BMS, Kevin worked in numerous therapeutic areas including neuroscience, cardiovascular, anti-infectives, psychiatry, GI, endocrinology and women’s health. Kevin completed his B.S. in Business Administration at Murray State University and has completed the INSEAD International Executive Study Program in France and Singapore.
Chief Financial Officer
Jason brings to Arbor over 20 years of progressive accounting, auditing and finance experience from a mixture of public and private companies. Prior to Arbor, Jason managed the accounting function and was responsible for all SEC filings at Lodgian, Inc., an owner and operator of franchised hotels. Jason also successfully founded his own company specializing in Sarbanes-Oxley implementations and internal control consulting for some of the top public companies in Atlanta. In addition, Jason also worked for PwC in their audit function specializing in real estate and manufacturing. Jason is a Certified Public Accountant in the state of Georgia and a graduate of Ohio University with dual bachelor’s degrees in Accounting and Management Information Systems.
President and Chief Operating Officer
Thom Rowland is an industry veteran who started his career as a sales representative for UCB Pharmaceuticals. Thom later held various marketing positions with UCB prior to taking the position of head of marketing for Scandipharm. He played a lead role in turning the Scandipharm business around prior to its sale to Axcan Pharmaceuticals. Thom then served as a Vice President of Sales and Marketing for several business units at Solvay Pharmaceuticals where he was again instrumental in turning around an underperforming area. Thom was one of the founders of Ventrus Biosciences which completed a successful IPO in 2010.
Chief Executive Officer
Ed Schutter has over thirty years of pharmaceutical industry experience and was previously President of Sciele (Shionogi) Pharmaceuticals prior to joining Arbor. Prior to Sciele, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA. Ed is a registered pharmacist with a degree in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. He is currently a board member of Vitruvias Therapeutics, Vensun Pharmaceuticals, Establishment Labs, and Mercer University.